ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
NAV
₹44.12
as of 21 Oct 2026
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is an open-ended Sectoral/ Thematic scheme from ICICI Prudential Mutual Fund managing ₹6,861 crore (as of 30 Sept 2026). Its Direct-plan NAV is ₹44.12 as of 21 Oct 2026. The expense ratio is 1.31% a year. Managed by Dharmesh Kakkad. This page is factual data only – it carries no rating and no recommendation.
Key facts
- Expense ratio
- 1.31% / yr
- as of 31 Aug 2026
- Fund size
- ₹6,861 crore
- as of 30 Sept 2026
- Exit load
- 1%
- SIP available
- Yes
- Launched
- 12 Jul 2018
- ISIN
- INF109KC1GH2
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from nyvo’s own NAV data.
Rebased to 100data to 19 Oct 2026Benchmark: Nifty 500 Healthcare TRI
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
₹208
+108% on ₹100 over 5.0 yrs
Sectoral/ Thematic average
₹196
+96% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | -6.82% | -4.74% | -2.08 |
| 6 months | 4.34% | -1.28% | +5.62 |
| 1 year | 1.37% | -3.03% | +4.40 |
| 3 years (CAGR) | 20.33% | 12.47% | +7.86 |
| 5 years (CAGR) | 15.20% | 11.13% | +4.07 |
Category average across 135 funds, as of 19 Oct 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible – read that number first.
1-year holding periods
- Worst
- -8.5%
- Median
- 14.5%
- Best
- 64.8%
49 windows over the last 60 months, stepped monthly; 86% ended positive. Worst window began 1 Oct 2021. Windows overlap – this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 21.3%
- Median
- 26.6%
- Best
- 30.8%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 3 Oct 2023. Windows overlap – this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.89
- Sharpe ratio (5Y)
- 0.65
- Sortino ratio (3Y)
- 1.51 vs category 1.37
- Standard deviation (3Y)
- 16.40%
- Beta (3Y)
- 0.96
- Alpha (3Y)
- 1.06%
- Deepest fall (5Y)
- -15.64%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high – how deep and for how long is what a drawdown feels like.
Deepest fall
-15.6%
Right now
-7.7% below peak
Ahead of its benchmark in 50% of months (window: 3y, monthly) – benchmark: Nifty 500 Healthcare TRI, name shown only.
Where the money actually is
Equity
98.9%
Cash
1.1%
Whole-portfolio split, as of 30 Sept 2026.
What it owns
42 positions · top 10 = 57.8%
Market-cap mix
Large 23.4%Mid 32.0%Small 42.7%Other 2.0%
as of 30 Sept 2026
Holdings by sector
Healthcare(9 in top 10)97.7%
- Sun Pharmaceuticals Industries Ltd11.49%
- Dr Reddy's Laboratories Ltd9.73%
- Cipla Ltd5.79%
- Biocon Ltd5.33%
- Mankind Pharma Ltd5.04%
- Alkem Laboratories Ltd4.81%
- Medplus Health Services Ltd4.31%
- Cohance Lifesciences Ltd4.06%
- Divi's Laboratories Ltd3.78%
- Basic Materials1.2%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 30 Sept 2026. Portfolio turnover 56.7% vs category 39.1% a year.
Other top holdings
- Treps4.25%
The businesses it owns
- P/E (trailing)
- 37.4 vs category 25.0
- P/B
- 4.1 vs category 3.8
- Dividend yield
- 0.7% vs category 1.1%
- Net margin
- 13.0% vs category 15.1%
- Earnings growth
- 13.1%
- Avg market cap
- ₹44,831 crore
Money in, money out
- Net flow, 12 months
- +₹59 cr
- Net flow, 3 months
- +₹348 cr
as of 30 Sept 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- ₹44.12 per unit as of 21 Oct 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- 1.31% a year for the Direct plan, as of 31 Aug 2026.
- How large is ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- ₹6,861 crore under management as of 30 Sept 2026, in the Sectoral/ Thematic category.
- How risky is ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- 15.20% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 11.13%. Past returns do not predict future returns.
- What is the worst 3-year return of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- 21.3% a year – the weakest of 25 overlapping 3-year holding periods, beginning 3 Oct 2023. The median was 26.6% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- Dharmesh Kakkad, managing this fund for 6.4 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund – growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹36,469 crore
- ICICI Prudential Business Cycle Fund₹14,889 crore
- ICICI Prudential Technology Fund₹12,505 crore
- HDFC Defence Fund₹11,493 crore
- Nippon India Banking & Financial Services Fund₹7,367 crore
- ICICI Prudential Manufacturing Fund₹6,918 crore
- SBI MNC FUND₹6,381 crore
- SBI PSU FUND₹6,354 crore
Data: nyvo research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.